VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-07-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aimed to use pharmacogenetic information in clinical practise which may lead to rapid, efficient, and safe warfarin dosing in this observational prospective study. In this context, the investigators plan to develop an algorithm for estimating the appropriate warfarin dose that is based on both clinical and genetic data from the Turkish study population. This study is unique not only investigating clinical factors, demographic variables, CYP2C9, and VKORC1 gene variations which contribute to the variability among patients in dose requirements for warfarin but also including thrombogenic single nucleotide polymorphisms (SNP) in the same patient population. Thus, warfarin would be a good example by being the first cardiovascular drug for pharmacogenetic guided "personalized medicine" applications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin

NCT01119300

Venous Thromboembolism Atrial Fibrillation

COMPLETED PHASE4

Genotype-Guided Warfarin Therapy Trial

NCT00904293

Atrial Fibrillation Deep Vein Thrombosis Pulmonary Embolism +1 more

COMPLETED NA

Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial

NCT00654823

Cardiovascular Diseases

UNKNOWN

Pharmacogenetic Dosing of Warfarin

NCT02065388

Stroke Venous Thrombosis Atrial Fibrillation +1 more

COMPLETED PHASE3

Genetic Determinants of Warfarin Anticoagulation Effect

NCT00162435

Venous Thrombosis Pulmonary Embolism Atrial Fibrillation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Long-term anticoagulation therapy with warfarin is recommended for patients with atrial fibrillation/flutter (AF), left atrial thrombus, deep vein thrombosis (DVT), pulmonary thromboembolism (PE), mechanical heart valve replacement, cardiomyopathy, and ischemic stroke. Warfarin, a coumarin derivative, produces an anticoagulant effect by interfering with the vitamin K 2,3 epoxide reductase (VKOR) enzyme and γ-carboxylation of vitamin K-dependent clotting factors such as II, VII, IX, and X. However, management of warfarin therapy is complicated with interindividual differences in drug response, delayed onset of action, difficulty with reversal and a narrow therapeutic window leading to increased risk of life-threatening hemorrhagic adverse events or thromboembolism. Furthermore, in order to determine safe and effective loading dose during the early phase of therapy and maintenance doses require frequent laboratory monitoring and adjustments to compensate for changes in patients' age, body size, vitamin K intake through diet, disease state, comorbidities, concomitant use of other medications, and patient-specific genetic factors.

Poor anticoagulant control may cause fatal complications such as thromboembolism with undertreatment or bleeding with excessive anticoagulation. Indeed, the risk of major bleeding in patients on warfarin is between 1% and 5% per year. Identifying the optimal therapeutic range and managing the dose of therapy to achieve the maximal time in therapeutic range are two of the most important determinants of therapeutic effectiveness and of reducing hemorrhagic risk. Currently, there have been substantial efforts to improve the safety of warfarin anticoagulation therapy. Recent warfarin pharmacogenetic studies have largely focused on two candidate genes: CYP2C9, responsible for warfarin metabolism, and VKORC1, which encodes vitamin K epoxide reductase, the site of warfarin action. Current evidence is clear that polymorphisms in either CYP2C9 or VKORC1 affect warfarin sensitivity.

We aimed to use pharmacogenetic information in clinical practise which may lead to rapid, efficient, and safe warfarin dosing in this observational prospective study. In this context, we plan to develop an algorithm for estimating the appropriate warfarin dose that is based on both clinical and genetic data from the Turkish study population. This study is unique not only investigating clinical factors, demographic variables, CYP2C9, and VKORC1 gene variations which contribute to the variability among patients in dose requirements for warfarin but also including thrombogenic single nucleotide polymorphisms (SNP) in the same patient population. Thus, warfarin would be a good example by being the first cardiovascular drug for pharmacogenetic guided "personalized medicine" applications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Cardiac Thrombus Deep Vein Thrombosis Pulmonary Embolism Heart Valve Replacement (Mechanical or Biological With AF) Cardiomyopathy (Ischemic or Dilated) Peripheral Vascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Warfarin dose titration

Dosage

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients who require warfarin for at least 6 months with the indications listed below:

* Permanent Atrial Fibrillation/Flutter
* Left atrial or ventricular thrombus
* Deep Vein Thrombosis
* Pulmonary Embolism
* Heart Valve Replacement (Mechanical or Biological With AF)
* Cardiomyopathy (Ischemic or Dilated)
* Peripheral Vascular Disease

Exclusion Criteria

* History of GI bleeding or peptic ulcer disease
* Significant liver disease, active hepatitis or chronic HBV/HCV infection
* Uncontrolled hypertension
* Chronic diarrhea or malabsorption syndrome
* Viral or bacterial infection prior to enrollment
* Active or previous infective endocarditis
* Hospital stay \> 30 days as a result of septicemia, mediastinitis or pneumonia
* Cardiac cachexia
* Morbid obesity
* Expected pregnancy, pregnancy or lactation
* Psychiatric disease
* Malignancy with Life expectancy less than 1 year

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No